Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on January 29, 2023. The report discloses a material corporate event regarding the departure of a principal officer, effective July 3, 2023.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and departure terms.
Material Changes
The primary material change reported is the resignation of Dr. Rupert Vessey, Executive Vice President, Research and Early Development. His departure is scheduled to take effect on July 3, 2023.
Management Commentary, Risks, and Unusual Items
Management has outlined the specific severance and equity arrangements for Dr. Vessey in connection with his departure:
- Severance: Benefits in accordance with the Senior Executive Severance Plan.
- Equity Vesting: Pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs); full vesting of the 2019 Restricted Stock Units Inducement Award.
- Annual Incentive: A pro-rated 2023 annual incentive payout of $550,855.
No other risks, contingencies, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the exact effective date of Dr. Vessey's departure (July 3, 2023).
- Confirm the total value of the pro-rated annual incentive payout ($550,855).
- Review the terms of the Senior Executive Severance Plan to understand the full scope of cash benefits.
- Assess the impact of the departure on the Research and Early Development pipeline.